Study summary
A daily pill held IDH-mutant gliomas in check and delayed radiation and chemotherapy
-1.3%tumor growth rate every 6 months, vs +14.4% with placebo
What was tested
Vorasidenib, a pill that blocks the mutant IDH1 and IDH2 enzymes driving these tumors, against placebo, for grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery, in people who had not yet needed radiation or chemotherapy.
What they found
- Risk of progression was 65% lower (hazard ratio 0.35); median progression-free survival was 11.4 months on placebo and not yet reached on vorasidenib.
- Tumors shrank slightly (-1.3% every 6 months) vs grew 14.4% with placebo.
- Quality of life and thinking skills were preserved, and seizures were less frequent.
What it means
The first targeted drug for these brain tumors; lets many people postpone radiation and chemotherapy and their effects on memory.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.